Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emibetuzumab + Ramucirumab in Advanced Cancer
NCT02082210Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of emibetuzumab in solid tumor (advanced stage), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-Limiting Toxicities and Overall Response Rate up to 17 months. Started Mar 2014; status: completed.
02
Drugs
emibetuzumab
03
Conditions
solid tumor (advanced stage)gastric adenocarcinomagastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02082210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082210.